Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Salgia

Showing results (11-20 of 528) with videos related to

Pageof 53
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2022
Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor ReceptorMartin Sattler, Ravi Salgia
Translational Lung Cancer Research|July 10, 2023
LSD1-targeted therapy-a multi-purpose key to unlock immunotherapy in small cell lung cancerMartin Sattler, Ravi Salgia
Journal of Oncology Practice|June 13, 2018
Managing Patients With Relapsed Small-Cell Lung CancerJun Gong, Ravi Salgia
Trends in Cancer|February 21, 2018
The Genetic/Non-genetic Duality of Drug 'Resistance' in CancerRavi Salgia, Prakash Kulkarni
Journal of Carcinogenesis|February 26, 2009
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancerNeelu Puri, Ravi Salgia
Update on Cancer Therapeutics|April 7, 2010
The MET axis as a therapeutic targetMartin Sattler, Ravi Salgia
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2016
MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung CancerMartin Sattler, Ravi Salgia
Hematology/Oncology Clinics of North America|April 19, 2005
Novel therapies in lung cancerOlwen Hahn, Ravi Salgia
Anti-Cancer Agents in Medicinal Chemistry|November 30, 2007
Non-receptor tyrosine kinase inhibitors in lung cancerOlwen Hahn, Ravi Salgia
Hematology/Oncology Clinics of North America|December 6, 2005
Molecular biology of malignant mesothelioma: a reviewEvan Pisick, Ravi Salgia
Pageof 53

Showing results (11-20 of 528) with videos related to

Sort By:
Pageof 53
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2022
Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor ReceptorMartin Sattler, Ravi Salgia
Translational Lung Cancer Research|July 10, 2023
LSD1-targeted therapy-a multi-purpose key to unlock immunotherapy in small cell lung cancerMartin Sattler, Ravi Salgia
Journal of Oncology Practice|June 13, 2018
Managing Patients With Relapsed Small-Cell Lung CancerJun Gong, Ravi Salgia
Trends in Cancer|February 21, 2018
The Genetic/Non-genetic Duality of Drug 'Resistance' in CancerRavi Salgia, Prakash Kulkarni
Journal of Carcinogenesis|February 26, 2009
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancerNeelu Puri, Ravi Salgia
Update on Cancer Therapeutics|April 7, 2010
The MET axis as a therapeutic targetMartin Sattler, Ravi Salgia
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2016
MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung CancerMartin Sattler, Ravi Salgia
Hematology/Oncology Clinics of North America|April 19, 2005
Novel therapies in lung cancerOlwen Hahn, Ravi Salgia
Anti-Cancer Agents in Medicinal Chemistry|November 30, 2007
Non-receptor tyrosine kinase inhibitors in lung cancerOlwen Hahn, Ravi Salgia
Hematology/Oncology Clinics of North America|December 6, 2005
Molecular biology of malignant mesothelioma: a reviewEvan Pisick, Ravi Salgia
Pageof 53